Azienda Ospedaliera Universitaria Delle Marche

Torrette 60020

0 studies enrolling now · 2 studies all time

What they study most

Esophageal Squamous Cell Carcinoma (ESCC), Gastric, or Gastroesophageal Junction Adenocarcinoma

Studies at this site

• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma — Completed